Tiziana partnership scoops innovation award

Clinical stage biotechnology company Tiziana Life Sciences was celebrating on Wednesday, after its partnership with researchers at Cardiff University collected a fresh award.

The AIM-traded company said the partnership, which has led to the development of a potential new drug for metastatic breast cancer, won the Innovation in Healthcare category at the university’s Innovation and Impact Awards 2016.

Its board said the venture, between Tiziana and a joint team from the European Cancer Stem Cell Research Institute and the School of Pharmacy and Pharmaceutical Sciences at Cardiff, has led to the identification of a small molecule inhibitor of Bcl3, which possesses potent anti-cancer properties for breast and colorectal metastatic cancer.

"Work on this project helped us to cement our relationship with Cardiff University and drives forward the new field of cancer stem cell therapeutics,” said Tiziana chairman Gabriele Cerrone.

“This award showcases the great work being done at Cardiff to identify inhibitors which can be developed into novel drugs for cancers."